A pegylated human IL-10 that activates tumor immunity21), pegilodecakin (PEG), in combination with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) has been evaluated in a phase III trial (SEQUOIA study) as a second-line treatment for patients with metastatic pancreatic cancer, but its improved efficacy was not demonstrated22). This evidence concerns the gene IL10 and neoplasm.